Management of cardiac sarcoidosis: A clinical consensus statement of the Heart Failure Association, the European Association of Cardiovascular Imaging, the ESC Working Group on Myocardial & Pericardial Diseases, and the European Heart Rhythm Association of the ESC

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F24%3A10483123" target="_blank" >RIV/00064165:_____/24:10483123 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/24:10483123

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=haI09C3KI1" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=haI09C3KI1</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1093/eurheartj/ehae356" target="_blank" >10.1093/eurheartj/ehae356</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Management of cardiac sarcoidosis: A clinical consensus statement of the Heart Failure Association, the European Association of Cardiovascular Imaging, the ESC Working Group on Myocardial & Pericardial Diseases, and the European Heart Rhythm Association of the ESC

Popis výsledku v původním jazyce

Cardiac sarcoidosis (CS) is a form of inflammatory cardiomyopathy associated with significant clinical complications such as high-degree atrioventricular block, ventricular tachycardia, and heart failure as well as sudden cardiac death. It is therefore important to provide an expert consensus statement summarizing the role of different available diagnostic tools and emphasizing the importance of a multidisciplinary approach. By integrating clinical information and the results of diagnostic tests, an accurate, validated, and timely diagnosis can be made, while alternative diagnoses can be reasonably excluded. This clinical expert consensus statement reviews the evidence on the management of different CS manifestations and provides advice to practicing clinicians in the field on the role of immunosuppression and the treatment of cardiac complications based on limited published data and the experience of international CS experts. The monitoring and risk stratification of patients with CS is also covered, while controversies and future research needs are explored. Graphical Abstract The multi-disciplinary team based approach to the diagnosis and treatment of cardiac sarcoidosis. CMR, cardiac magnetic resonance; CRT, cardiac resynchronization therapy; ECG, electrocardiogram; FDG-PET, fluorodeoxyglucose positron emission tomography; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardiac defibrillator; MDT, multidisciplinary team; NT-proBNP, N-terminal pro-B-type natriuretic peptide; RV, right ventricle; TNF, tumour necrosis factor.

Název v anglickém jazyce

Management of cardiac sarcoidosis: A clinical consensus statement of the Heart Failure Association, the European Association of Cardiovascular Imaging, the ESC Working Group on Myocardial & Pericardial Diseases, and the European Heart Rhythm Association of the ESC

Popis výsledku anglicky

Cardiac sarcoidosis (CS) is a form of inflammatory cardiomyopathy associated with significant clinical complications such as high-degree atrioventricular block, ventricular tachycardia, and heart failure as well as sudden cardiac death. It is therefore important to provide an expert consensus statement summarizing the role of different available diagnostic tools and emphasizing the importance of a multidisciplinary approach. By integrating clinical information and the results of diagnostic tests, an accurate, validated, and timely diagnosis can be made, while alternative diagnoses can be reasonably excluded. This clinical expert consensus statement reviews the evidence on the management of different CS manifestations and provides advice to practicing clinicians in the field on the role of immunosuppression and the treatment of cardiac complications based on limited published data and the experience of international CS experts. The monitoring and risk stratification of patients with CS is also covered, while controversies and future research needs are explored. Graphical Abstract The multi-disciplinary team based approach to the diagnosis and treatment of cardiac sarcoidosis. CMR, cardiac magnetic resonance; CRT, cardiac resynchronization therapy; ECG, electrocardiogram; FDG-PET, fluorodeoxyglucose positron emission tomography; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardiac defibrillator; MDT, multidisciplinary team; NT-proBNP, N-terminal pro-B-type natriuretic peptide; RV, right ventricle; TNF, tumour necrosis factor.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Heart Journal

ISSN

0195-668X

e-ISSN

1522-9645

Svazek periodika

45

Číslo periodika v rámci svazku

30

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

30

Strana od-do

2697-2726

Kód UT WoS článku

001254378800001

EID výsledku v databázi Scopus

2-s2.0-85200408671